AstraZeneca 的 Datopotamab Deruxtecan 在美國獲得轉移性肺癌的快速審查資格
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail.
阿斯利康和第一三共的datopotamab deruxtecan获得美国FDA的快速通道指定，用于治疗先前接受过全身治疗的晚期或转移性非鳞状非小细胞肺癌患者。
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, received US FDA Fast Track designation for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior systemic therapy. The designation is based on the TROPION-Lung01 Phase III trial, which showed a significant improvement in progression-free survival compared to standard chemotherapy.
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail. It strengthens AstraZeneca and Daiichi Sankyo's position in the competitive ADC market for oncology.
Where this signal fits in the broader landscape.
https://www.astrazeneca.com/media-centre/press-releases/2026/datopotamab-deruxtecan-granted-fast-track-designation-in-us-for-metastatic-non-small-cell-lung-cancer.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
登录